Dynavax Technologies Corporation Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
02 févr. 2018 16h30 HE
|
Dynavax Technologies Corporation
BERKELEY, Calif., Feb. 02, 2018 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (NASDAQ:DVAX) today announced that on February 1, 2018 the Compensation Committee of Dynavax’s Board of Directors...
Dynavax Technologies Corporation Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
12 janv. 2018 16h01 HE
|
Dynavax Technologies Corporation
BERKELEY, Calif., Jan. 12, 2018 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (NASDAQ:DVAX) today announced that on January 10, 2018 the Compensation Committee of Dynavax’s Board of Directors...
Dynavax Announces HEPLISAV-B™ is Now Available in the United States for the Prevention of Hepatitis B in Adults
08 janv. 2018 06h00 HE
|
Dynavax Technologies Corporation
BERKELEY, Calif., Jan. 08, 2018 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (NASDAQ:DVAX) today announced that HEPLISAV-B™ [Hepatitis B Vaccine (Recombinant), Adjuvanted] is now available...
Dynavax to Present at J.P. Morgan 36th Annual Healthcare Conference
04 janv. 2018 06h00 HE
|
Dynavax Technologies Corporation
BERKELEY, Calif., Jan. 04, 2018 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (NASDAQ:DVAX) announced today that Eddie Gray, Dynavax’s chief executive officer, will present at the J.P. Morgan...
Dynavax Technologies Corporation Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
05 déc. 2017 16h01 HE
|
Dynavax Technologies
BERKELEY, CA--(Marketwired - December 05, 2017) - Dynavax Technologies Corporation (NASDAQ: DVAX) today announced that on November 28, 2017 the Compensation Committee of Dynavax's Board of Directors...
Dynavax to Present at the Evercore ISI Biopharma Catalyst/Deep Dive Conference
27 nov. 2017 16h01 HE
|
Dynavax Technologies
BERKELEY, CA--(Marketwired - November 27, 2017) - Dynavax Technologies Corporation (NASDAQ: DVAX) announced today that Eddie Gray, Dynavax's chief executive officer, will present at the Evercore ISI...
Dynavax Announces FDA Approval of HEPLISAV-B(TM) for Prevention of Hepatitis B in Adults
09 nov. 2017 16h45 HE
|
Dynavax Technologies
BERKELEY, CA--(Marketwired - November 09, 2017) - Dynavax Technologies Corporation (NASDAQ: DVAX) today announced that the U.S. Food and Drug Administration (FDA) has approved HEPLISAV-B [Hepatitis...
Dynavax Reports Third Quarter 2017 Financial Results
03 nov. 2017 06h30 HE
|
Dynavax Technologies
BERKELEY, CA--(Marketwired - November 03, 2017) - Dynavax Technologies Corporation (NASDAQ: DVAX) today reported financial results for the third quarter ended September 30, 2017. Cash, cash...
Dynavax Initiates Clinical Trial in Non-Small Cell Lung Cancer with a Novel Inhaled TLR9 Agonist in Combination with Anti-PD-1 Therapy
19 oct. 2017 06h30 HE
|
Dynavax Technologies
BERKELEY, CA--(Marketwired - October 19, 2017) - Dynavax Technologies Corporation (NASDAQ: DVAX) announced initiation of dosing in a phase 1B dose escalation clinical trial of its investigational...
Dynavax to Present at Upcoming Investor Conferences
05 sept. 2017 06h00 HE
|
Dynavax Technologies
BERKELEY, CA--(Marketwired - September 05, 2017) - Dynavax Technologies Corporation (NASDAQ: DVAX) announced today that the company will present at two upcoming investor conferences in...